2004
DOI: 10.1016/j.archger.2004.04.040
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness and Safety of Cholinesterase Inhibitors in Elderly Subjects With Alzheimer’s Disease: A “Real World” Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
36
0
3

Year Published

2005
2005
2015
2015

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(40 citation statements)
references
References 0 publications
1
36
0
3
Order By: Relevance
“…In terms of cognitive function and functionality of treated patients, some studies have shown similar results among the 3 ChEIs [33,37,38] , while other studies have shown a significant advantage for one of them: rivastigmine [36,39,40] , galantamine [34] or donepezil [35,40] . However, no strict comparisons have been done with memantine.…”
Section: Discussionmentioning
confidence: 86%
See 1 more Smart Citation
“…In terms of cognitive function and functionality of treated patients, some studies have shown similar results among the 3 ChEIs [33,37,38] , while other studies have shown a significant advantage for one of them: rivastigmine [36,39,40] , galantamine [34] or donepezil [35,40] . However, no strict comparisons have been done with memantine.…”
Section: Discussionmentioning
confidence: 86%
“…Four clinical trials [33][34][35][36] and studies in the clinical setting [37][38][39][40] have compared different ChEIs in terms of the cognitive and functional outcomes of patients; however, there is no agreement in their results, leaving the extent of each drug's effect undetermined. Patient-reported outcomes are important to understand the impact that the treatment has on the patient's functioning and wellbeing, providing valuable information for evaluating the adequacy of treatment outcomes [41] and for regulatory decisions [42,43] .…”
Section: Introductionmentioning
confidence: 99%
“…Two of the included studies compared donepezil and rivastigmine only [23,24] , while the remaining 10 reported a head-to-head comparison of all 3 ChEIs [25][26][27][28][29][30][31][32][33][34] .…”
Section: Resultsmentioning
confidence: 99%
“…One study [34] was only available as an abstract and therefore reported limited study details, which resulted in a score of 4 on the NOS scale. The remaining 9 studies [23,[26][27][28][29][30][31][32][33] were judged to be of good quality (range: 7-9).…”
Section: Resultsmentioning
confidence: 99%
“…The clinical benefit of reaching higher doses from a QoL perspective is supported by a large 3-year, prospective, observational study of 880 patients with AD treated with CIs, in which a higher dose of CIs (donepezil >6.9 mg/ day, oral rivastigmine >6 mg/day, galantamine >16 mg/day) was independently associated with a lower institutionalization risk [Wattmo et al 2011]. The risk of gastrointestinal side effects leading to treatment withdrawal is particularly high for the oral formulation of rivastigmine, both in clinical trials [Birks et al 2009] and in clinical practice [Mossello et al 2004]. In this regard, the introduction of a transdermal formulation of rivastigmine has represented a relevant advantage, allowing the administration of higher, more efficacious doses with a reduction of adverse events by two-thirds in comparison with capsules [Winblad et al 2007].…”
Section: Adverse Events Risk Versus Efficacymentioning
confidence: 99%